Abstract | STUDY OBJECTIVES: DESIGN: Patients with pleural thymoma metastases or early-stage MPM were enrolled in a feasibility study. Morbidity, recurrence, and survival rates were recorded. SETTING: The Netherlands Cancer Institute. PATIENTS: INTERVENTIONS: MEASUREMENTS AND RESULTS: Morbidity and mortality rates were 47% and 0%, respectively. Reoperation was necessary in four cases. Severe chemotherapy-related complications were not observed. A solitary mediastinal and a contralateral pleural thymoma recurrence were successfully treated by radiotherapy and a contralateral HITHOC procedure. All thymoma patients were alive and free of disease after a mean follow-up period of 18 months. After a mean follow-up period of 7.4 months, nine mesothelioma patients are alive. Two mesothelioma patients died of contralateral pleural and peritoneal recurrent disease, while one patient is alive with locoregional recurrence. CONCLUSIONS:
Cytoreductive surgery and HITHOC with cisplatin and adriamycin is feasible in patients with pleural thymoma metastases and early-stage MPM, and is associated with acceptable morbidity rates. Early data on locoregional disease control are encouraging, and a phase II study will be conducted.
|
Authors | Eelco de Bree, Serge van Ruth, Paul Baas, Emiel J Th Rutgers, Nico van Zandwijk, Arjen J Witkamp, Frans A N Zoetmulder |
Journal | Chest
(Chest)
Vol. 121
Issue 2
Pg. 480-7
(Feb 2002)
ISSN: 0012-3692 [Print] United States |
PMID | 11834661
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Doxorubicin
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Doxorubicin
(administration & dosage)
- Feasibility Studies
- Female
- Follow-Up Studies
- Humans
- Male
- Mesothelioma
(therapy)
- Middle Aged
- Pleural Neoplasms
(drug therapy, secondary, surgery, therapy)
- Survival Rate
- Thymoma
(pathology, secondary, therapy)
- Thymus Neoplasms
(pathology)
|